Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.41 |
| ▸ | KDM5A | P29375 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30154426 | 0.89 | EGLN1 (0.50) | EGLN1 | |
| SCHEMBL16109841 | 0.89 | EGLN1 (0.50) | EGLN1 | |
| SCHEMBL30154492 | 0.83 | KDM4C (0.43) | EGLN1KDM4CLMNA | |
| SCHEMBL23832249 | 0.83 | KDM4C (0.43) | EGLN1KDM4CLMNA | |
| SCHEMBL16109624 | 0.83 | MAP4K4 (0.48) | EGLN1 | |
| SCHEMBL30154453 | 0.81 | KDM4C (0.45) | EGLN1KDM5AKDM4CKDM5B | |
| SCHEMBL23832196 | 0.81 | KDM4C (0.45) | EGLN1KDM5AKDM4CKDM5B | |
| SCHEMBL23832261 | 0.81 | EGLN1 (0.47) | EGLN1KDM4CLMNA | |
| SCHEMBL20275461 | 0.81 | EGLN1 (0.50) | EGLN1 | |
| SCHEMBL16110510 | 0.81 | EGLN1 (0.47) | EGLN1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823097-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-115551845-B | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4121425-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115551845-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021188936-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188936-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | EGLN1 11/4885KDM5A 72/4885KDM4C 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.